MedTrace Logo

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

NCT02922946 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2018-08-16

No results posted yet for this study

Summary

The objectives of this study are to evaluate the effect of the timing of a moderate-fat meal on the single dose pharmacokinetics of entinostat and to evaluate the safety and tolerability of entinostat under fed and fasting conditions in healthy adult subjects.

Conditions

  • Volunteers
  • Healthy Volunteers
  • Human Volunteers
  • Normal Volunteers

Interventions

DRUG

Entinostat

HDAC (histone deacetylase) inhibitor

Sponsors & Collaborators

Principal Investigators

  • Laura Sterling, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-11
Primary Completion
2017-05-20
Completion
2017-06-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02922946 on ClinicalTrials.gov